Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.01%

By Michael Rose
August 01, 2026
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Revolution Medicines, Inc. before investing.

In this article, we go over a few key elements for understanding Revolution Medicines, Inc.’s stock price such as:

  • Revolution Medicines, Inc.’s current stock price and volume
  • Why Revolution Medicines, Inc.’s stock price changed recently
  • Upgrades and downgrades for RVMD from analysts
  • RVMD’s stock price momentum as measured by its relative strength

About Revolution Medicines, Inc. (RVMD)

Before we jump into Revolution Medicines, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Want to learn more about Revolution Medicines, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Revolution Medicines, Inc..

Learn More About A+ Investor

Revolution Medicines, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Revolution Medicines, Inc.’s stock price was $187.530.

Revolution Medicines, Inc. is down 2.41% from its previous closing price of $192.170.

During the last market session, Revolution Medicines, Inc.’s stock traded between $186.150 and $192.000. Currently, there are approximately 198.10 million shares outstanding for Revolution Medicines, Inc..

Revolution Medicines, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Revolution Medicines, Inc. Stock Price History

Revolution Medicines, Inc.’s (RVMD) price is currently up 0.13% so far this month.

During the month of July, Revolution Medicines, Inc.’s stock price has reached a high of $194.560 and a low of $176.000.

Over the last year, Revolution Medicines, Inc. has hit prices as high as $194.560 and as low as $34.000. Year to date, Revolution Medicines, Inc.’s stock is up 135.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Revolution Medicines, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Revolution Medicines, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Revolution Medicines, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Revolution Medicines, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Revolution Medicines, Inc. (RVMD) by visiting AAII Stock Evaluator.

Relative Price Strength of Revolution Medicines, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Revolution Medicines, Inc. has a weighted four-quarter relative price strength of 41.35%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Revolution Medicines, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Revolution Medicines, Inc. Stock Price: Bottom Line

As of July 31, 2026, Revolution Medicines, Inc.’s stock price is $187.530, which is down 2.41% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Revolution Medicines, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
O'Neil CAN SLIM Screen: 38.3% Compared to S&P 500
at only 23.3%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.